SHR-1905 clinical trials
Also written SHR-1905.
How each study uses SHR-1905 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SHR-1905 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Guangdong Hengrui Pharmaceutical Co., Ltd (5) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1) · Atridia Pty Ltd. (1)
Studies
Open first, then newest update. How each study uses SHR-1905 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic DermatitisRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07211542Written as SHR-1905 Injection
- Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal PolypsRecruitingPhase 3Guangdong Hengrui Pharmaceutical Co., LtdNCT07132827Written as SHR-1905 Injection
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaRecruitingPhase 3Guangdong Hengrui Pharmaceutical Co., LtdNCT07098403Written as SHR-1905 Injection
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaCompletedPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05593250Written as SHR-1905
- Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT05891483Written as SHR-1905 Injection
- Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical StudyCompletedPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT06786455Written as SHR-1905 Injection
- A Trial of SHR-1905 in Healthy SubjectsCompletedPhase 1Atridia Pty Ltd.NCT04800263Written as SHR-1905